MedTrace Logo

Dexmedetomidine Versus Fentanyl as an Adjuvant to Bupivacaine in Saddle Block

NCT06216197 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2024-01-22

No results posted yet for this study

Summary

Dexmedetomidine is recommended over fentanyl as adjunctive medication to bupivacaine for saddle block spinal anesthesia in anal surgeries and procedures.

Conditions

  • Regional Anesthesia Morbidity

Interventions

DRUG

FENT group

Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 μg).

DRUG

DEX group

The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 μg; 0.5 ml).

Sponsors & Collaborators

  • Zulekha Hospitals

    lead OTHER

Principal Investigators

  • sameh ha seyam, MD · assistant professor of anesthesiology, intensive care and pain management

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-03
Primary Completion
2022-12-04
Completion
2022-12-04

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06216197 on ClinicalTrials.gov